Methods and compositions for treating trauma-hemorrhage using estrogen and derivatives thereof
Disclosed are methods and materials for treating or preventing complications due to traumatic injuries using estrogen or derivatives thereof.
1. A method of ameliorating one or more effects of a traumatic injury in a subject, the method comprising administering 17α-ethinylestradiol-3-sulfate to the subject in a low volume of solution, wherein the 17α-ethinylestradiol-3-sulfate is in a water-soluble form and is administered prior to fluid resuscitation.
2. The method of claim 1 , wherein 0.5 ml/kg or less of 17α-ethinylestradiol-3-sulfate in water-soluble form is administered to the subject.
3. The method of claim 1 , wherein the 17α-ethinylestradiol-3-sulfate is in a cyclodextrin complex.
4. The method of claim 3 , wherein the cyclodextrin complex comprises 2-hydroxypropyl-β-cyclodextrin or sulfobutyl ether cyclodextran.
5. The method of claim 1 , wherein the administration is intravenous or intraosseous.
6. The method of claim 1 , wherein the 17α-ethinylestradiol-3-sulfate is administered with 17α-estradiol, 17α-estradiol sulfate, β-estradiol, 17β-estradiol sulfate, 17β-estradiol-3-sulfate, or equiline sulfate.
7. The method of claim 1 , wherein the traumatic injury is traumatic brain injury.
8. The method of claim 1 , wherein the traumatic injury involves an inflammatory response or low blood pressure compared to a control blood pressure or severe blood loss.
9. The method of claim 1 , wherein administration of 17α-ethinylestradiol-3-sulfate maintains a state of permissive hypotension.
10. The method of claim 1 , wherein the 17α-ethinylestradiol-3-sulfate is administered after the traumatic injury but prior to treatment.
11. The method of claim 1 , wherein the 17α-ethinylestradiol-3-sulfate is administered at between 0.3 and 3.0 mg/kg.
12. A method of ameliorating one or more effects of severe blood loss in a subject, the method comprising administering 17α-ethinylestradiol-3-sulfate to the subject, wherein the 17α-ethinylestradiol-3-sulfate is in water-soluble form and is administered prior to fluid resuscitation.
13. The method of claim 12 , wherein 0.5 ml/kg or less of 17α-ethinylestradiol-3-sulfate in water soluble form is administered to the subject.
14. The method of claim 12 , wherein the administration is intravenous or intraosseous.
15. The method of claim 12 , wherein the 17α-ethinylestradiol-3-sulfate is administered with 17α-estradiol, 17α-estradiol sulfate, β-estradiol, 17β-estradiol sulfate, 17β-estradiol sulfate or equiline sulfate.
16. The method of claim 12 , wherein the 17α-ethinylestradiol-3-sulfate is administered after the severe blood loss but prior to treatment.
17. A method of prolonging viability of tissue, organ, cell, or an entire body for donation, the method comprising contacting the tissue, organ, cell, or entire body with 17α-ethinylestradiol-3-sulfate.
18. The method of claim 17 , wherein the 17α-ethinylestradiol-3-sulfate is administered with 17α-estradiol, 17α-estradiol sulfate, β-estradiol, 17β-estradiol sulfate, 17β-estradiol-3-sulfate, or equiline sulfate.
19. The method of claim 17 , wherein the contacting step is performed in vivo by administering 17α-ethinylestradiol-3-sulfate to a donor.
20. The method of claim 17 , wherein the contacting step is performed ex vivo.